Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Listing-Obligations-and-Disclosure-Requirements"

9 News Found

Dr. Reddy’s to participate in HSBC, Bank of America investor conferences
News | May 12, 2026

Dr. Reddy’s to participate in HSBC, Bank of America investor conferences

Pharma major to engage with institutional investors through group meetings in Mumbai and Singapore during May 2026


Alkem Laboratories receives relief as GST demand of Rs 69.65 crore dropped on appeal
News | May 06, 2026

Alkem Laboratories receives relief as GST demand of Rs 69.65 crore dropped on appeal

The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty


Sai Life Sciences allots 2.44 lakh equity shares under employee stock option schemes
News | April 24, 2026

Sai Life Sciences allots 2.44 lakh equity shares under employee stock option schemes

Shares issued under ESOP 2008 and MESOP 2018 plans following exercise of vested stock options, in compliance with SEBI disclosure norms


Shilpa Medicare appoints Dr Vellaian Karuppiah as COO – Formulations
People | April 24, 2026

Shilpa Medicare appoints Dr Vellaian Karuppiah as COO – Formulations

Veteran pharma leader brings 33+ years of experience to drive operational excellence in formulation business


Zorvia opposes adjournment in defamation case against Emcure, Zuventus before Thane Court
News | April 20, 2026

Zorvia opposes adjournment in defamation case against Emcure, Zuventus before Thane Court

The dispute stems from an earlier circular by Zuventus allegedly accusing Zorvia of market sabotage


Zydus improves ESG rating to 68, up from 66 last year
News | April 11, 2026

Zydus improves ESG rating to 68, up from 66 last year

The improved score reflects a stronger ESG profile for the Ahmedabad-based drugmaker


Max Healthcare allots 57,461 equity shares under ESOP 2022
Hospitals | April 05, 2026

Max Healthcare allots 57,461 equity shares under ESOP 2022

Paid-up equity capital rises to Rs 973.19 crore following allotment to eligible employees


Zydus receives EIR for the transdermal manufacturing facility
Drug Approval | October 02, 2024

Zydus receives EIR for the transdermal manufacturing facility

This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated


U.S. FDA concludes inspection of Lupin’s Goa facility with seven observations
News | September 20, 2021

U.S. FDA concludes inspection of Lupin’s Goa facility with seven observations

The company said in a regulatory filing that it was confident of addressing the observations satisfactorily